Screener
BridgeBio Pharma BBIO Gross Carrying Amount
Gross Carrying Amount at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | June 30, 2026 / Weighted-average Estimated Useful Lives | June 30, 2026 / Amount | December 31, 2025 / Weighted-average Estimated Useful Lives | December 31, 2025 / Amount |
|---|---|---|---|---|
| Gross amount | 13.7 years | $39,400 | 13.7 years | $39,400 |
| Less accumulated amortization | (12,759) | (11,323) | ||
| Total | $26,641 | $28,077 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's gross carrying amount?
- BridgeBio Pharma (BBIO) reported gross carrying amount of $39.4M in Q2 2026.
- What does gross carrying amount mean?
- Gross Carrying Amount
Ask your AI about BridgeBio Pharma's gross carrying amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude